<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11216">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591864</url>
  </required_header>
  <id_info>
    <org_study_id>07-003397</org_study_id>
    <nct_id>NCT00591864</nct_id>
  </id_info>
  <brief_title>Comparison of MRI and Molecular Breast Imaging in Breast Diagnostic Evaluation</brief_title>
  <acronym>MBI</acronym>
  <official_title>Comparison of Magnetic Resonance Imaging and Molecular Breast Imaging in Breast Diagnostic Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the sensitivity of Molecular Breast Imaging (MBI)
      relative to MRI of the breast in patients undergoing MRI for a clinical concern, or abnormal
      diagnostic mammogram and/or ultrasound study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Breast MRI has excellent sensitivity, but is very expensive and suffers from low
      specificity. Additional benign biopsies are prompted by MRI in 24-40% of patients. Molecular
      Breast Imaging (MBI) is a new nuclear medicine technique developed at Mayo. Preliminary MBI
      results indicate a sensitivity of ~88% for the detection of tumors &lt; 10 mm. The cost of an
      MBI procedure is expected to be a factor of 5 less than an MRI examination.

      Hypothesis: MBI has a comparable sensitivity to MRI at a significantly lower cost.

      Study Design: A total of 120 patients will be studied. All patients will have been scheduled
      for bilateral breast MRI at Mayo Clinic Rochester for a clinical concern, problem solving,
      or abnormal mammogram and/or ultrasound study. All patients will undergo MBI within 3 weeks
      of the MRI examination.

      Potential Outcomes: This study will provide valuable information on the sensitivity of MBI
      relative to MRI, and to determine if this new technique can be eventually developed as an
      alternative to MRI for problem solving.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Sensitivity on the Per Patient Level</measure>
    <time_frame>within 1 week of surgery or biopsy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sensitivity is the number of women with breast cancer detected per number of women with breast cancer diagnosed by surgery or biopsy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity on the Per Tumor Level</measure>
    <time_frame>within 1 week of surgery or biopsy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of tumors detected per number of tumors diagnosed on surgery or biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>at least one year following imaging</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of women with negative imaging test per number of women without cancer.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Molecular Breast Imaging</intervention_name>
    <description>Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  This study will include a population of women aged 25 or older who are scheduled for
             a breast MRI examination at MAYO CLINIC ROCHESTER.

          -  Patients must not be lactating or pregnant.

          -  All women of child-bearing potential must have had a negative urine pregnancy test
             result within 2 days prior to the MBI study.

          -  women who are scheduled for a breast MRI examination for a clinical concern, problem
             solving or for further evaluation of invasive breast cancer (e.g. pre-operative
             staging of known breast cancer).

        Exclusion Criteria:

          -  They are unable to understand and sign the consent form

          -  They are pregnant or lactating

          -  They are physically unable to sit upright and still for 40 minutes.

          -  The breast MRI is for screening purposes or to determine the status of breast
             augmentation.

          -  They have undergone breast surgery within the previous year
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <link>
    <url>http://newsblog.mayoclinic.org/2008/09/03/breast-cancer-molecular-breast-imaging-mammography/</url>
    <description>Mayo Clinic News Blog</description>
  </link>
  <link>
    <url>http://www.youtube.com/watch?v=DOQBLe8MdH0</url>
    <description>Mayo Clinic You Tube Channel</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 6, 2014</lastchanged_date>
  <firstreceived_date>December 21, 2007</firstreceived_date>
  <firstreceived_results_date>March 7, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Amy L. Conners</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Benign breast disease</keyword>
  <keyword>Breast</keyword>
  <keyword>MRI</keyword>
  <keyword>Mammography</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Molecular Breast Imaging</keyword>
  <keyword>Breast Cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Participants Imaged With MBI and MRI</title>
          <description>The group includes patients who underwent both MBI and breast MRI within the same 3 week period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Incomplete Imaging</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Participants</title>
          <description>There are no arms or subgroups in this study.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="89"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53" lower_limit="35" upper_limit="91"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="89"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity on the Per Patient Level</title>
        <description>Sensitivity is the number of women with breast cancer detected per number of women with breast cancer diagnosed by surgery or biopsy.</description>
        <time_frame>within 1 week of surgery or biopsy</time_frame>
        <safety_issue>No</safety_issue>
        <population>In the 84 patients who completed the study 28 were diagnosed with breast cancer.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Participants</title>
            <description>There are no arms or subgroups in this study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sensitivity on the Per Patient Level</title>
            <description>Sensitivity is the number of women with breast cancer detected per number of women with breast cancer diagnosed by surgery or biopsy.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Sensitivity by MBI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sensitivity by MRI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity on the Per Tumor Level</title>
        <description>Number of tumors detected per number of tumors diagnosed on surgery or biopsy.</description>
        <time_frame>within 1 week of surgery or biopsy</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Participants Imaged With MBI and MRI</title>
            <description>The group includes patients who underwent both MBI and breast MRI within the same 3 week period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of tumors analyzed</title>
            <units>tumors</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sensitivity on the Per Tumor Level</title>
            <description>Number of tumors detected per number of tumors diagnosed on surgery or biopsy.</description>
            <units>tumors</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>sensitivity by MBI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>sensitivity by MRI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specificity</title>
        <description>The number of women with negative imaging test per number of women without cancer.</description>
        <time_frame>at least one year following imaging</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Participants Imaged With MBI and MRI</title>
            <description>The group includes patients who underwent both MBI and breast MRI within the same 3 week period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Specificity</title>
            <description>The number of women with negative imaging test per number of women without cancer.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>specificity by MBI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>specificity by MRI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Study Participants</title>
          <description>There are no arms or subgroups in this study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy Lynn Conners MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>(507) 284-2511</phone>
      <email>MBI@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
